Loading…
Alterity Therapeutics Limited is projected to rise to $5.17 by 2027, a +28% move from its current price of $4.05. ATHE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.90 | $4.05 | $4.21 | +0.08% |
| May 30 | $3.84 | $4.06 | $4.29 | +0.16% |
| May 31 | $3.80 | $4.06 | $4.34 | +0.24% |
| Jun 1 | $3.76 | $4.06 | $4.39 | +0.33% |
| Jun 2 | $3.73 | $4.07 | $4.43 | +0.41% |
| Jun 3 | $3.70 | $4.07 | $4.48 | +0.49% |
| Jun 4 | $3.68 | $4.07 | $4.51 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.68 | $4.07 | $4.51 | +0.57% |
| Week 2 | $3.54 | $4.10 | $4.74 | +1.15% |
| Week 3 | $3.45 | $4.12 | $4.92 | +1.72% |
| Week 4 | $3.37 | $4.14 | $5.09 | +2.30% |
| Week 5 | $3.31 | $4.17 | $5.24 | +2.89% |
| Week 6 | $3.26 | $4.19 | $5.39 | +3.48% |
| Week 7 | $3.21 | $4.21 | $5.53 | +4.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alterity Therapeutics Limited is a healthcare company focused on research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple systematrophy, as well as biomarkers of progression in multiple system atrophy.
The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Alterity Therapeutics Limited (ATHE) is a healthcare company focused on neurodegenerative disorders. The current price is $4.14, and its market cap is $78.28M, with a rank of 4379.
Forecasts imply a path of rising prices over the coming years, with the average price moving from $4.14 in 2026 toward higher levels by 2030, 2040 and 2050, and a maximum forecast of $123.29 in 2050. The implied returns show growth across the forecast horizon, with an upside in later years and a bullish tilt in most years.
A major floor 28.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
The nearest ceiling, 27.2% above — a clean break opens room to run.
A major ceiling 41.5% above — clearing it would confirm fresh momentum.
Key ATHE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATHE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.14 | Sell | $4.14 | Sell |
| MA 10 | $4.27 | Sell | $4.25 | Sell |
| MA 20 | $4.45 | Sell | $4.32 | Sell |
| MA 50 | $4.08 | Sell | $4.15 | Sell |
| MA 100 | $3.74 | Buy | $3.96 | Buy |
| MA 200 | $3.96 | Buy | $3.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.57 | Neutral |
| Stoch RSI (14) | 3.83 | Buy |
| CCI (20) | -118.98 | Sell |
| Williams %R (14) | -97.50 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -13.09 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 2.50 | Buy |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 47.41 | Neutral |
| Momentum (10) | -0.78 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 4.05 | Buy |
| ADX (14) | 15.98 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day price range is $3.16 to $5.43, indicating a broad near-term trading band. RSI(14) stands at 40, with the near-term price dynamics influenced by momentum and volatility.
The near-term trend is supported by a SMA50 of $4.06 and a SMA200 of $3.97, with a defined support at $3.62 and resistance at $5.15. These levels place the stock in a constructive range, consistent with a bullish technical posture while still showing room for consolidation.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.02 | $4.05 | $5.37 | 0% | Neutral | |
| $3.93 | $5.17 | $7.28 | +28% | Bullish | |
| $4.55 | $6.23 | $9.20 | +54% | Bullish | |
| $5.94 | $8.42 | $12.92 | +108% | Bullish | |
| $6.79 | $9.91 | $15.70 | +145% | Bullish | |
| $6.48 | $9.73 | $15.83 | +140% | Bullish | |
| $7.16 | $11.06 | $18.44 | +173% | Bullish | |
| $7.44 | $11.77 | $20.06 | +191% | Bullish | |
| $7.24 | $11.74 | $20.43 | +190% | Bullish | |
| $9.00 | $14.94 | $26.48 | +269% | Bullish | |
| $12.29 | $22.78 | $43.61 | +462% | Bullish | |
| $24.14 | $53.65 | $114.79 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.02 | $4.05 | $4.81 | +0.00% |
| June 2026 | $3.66 | $4.33 | $5.29 | +7.02% |
| July 2026 | $3.64 | $4.36 | $5.42 | +0.64% |
| August 2026 | $3.53 | $4.27 | $5.39 | -2.11% |
| September 2026 | $3.61 | $4.41 | $5.63 | +3.25% |
| October 2026 | $3.65 | $4.49 | $5.78 | +1.73% |
| November 2026 | $3.43 | $4.24 | $5.52 | -5.46% |
| December 2026 | $3.29 | $4.09 | $5.37 | -3.45% |
Click any year to see its month-by-month ATHE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ATHE price prediction for 2026 points to an average of $4.05 (low $3.02, high $5.37) — a potential gain of 0% on today's $4.05. A consolidation phase looks the most probable path here.
In 2027, ATHE is projected to trade between $3.93 and $7.28, averaging $5.17 — a potential gain of +28% from today's $4.05. That is up +28% on the projected 2026 average. Momentum favours further upside here.
Alterity Therapeutics Limited's 2028 outlook centres on $6.23, within a $4.55 to $9.20 range. That is up +21% on the projected 2027 average. That marks a +54% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ATHE could reach as high as $12.92, with a base case around $8.42 and support toward $5.94 — roughly +108% from $4.05. Momentum favours further upside here.
Expect ATHE to range from $6.79 to $15.70 through 2030. The $9.91 average target implies a +145% move from current prices. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ATHE price prediction for 2031 points to an average of $9.73 (low $6.48, high $15.83) — a potential gain of +140% on today's $4.05. Momentum favours further upside here.
In 2032, ATHE is projected to trade between $7.16 and $18.44, averaging $11.06 — a potential gain of +173% from today's $4.05. That is up +14% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Alterity Therapeutics Limited's 2033 outlook centres on $11.77, within a $7.44 to $20.06 range. That is up +6% on the projected 2032 average. That marks a +191% change versus current levels. Momentum favours further upside here.
By 2034, ATHE could reach as high as $20.43, with a base case around $11.74 and support toward $7.24 — roughly +190% from $4.05. Buyers look set to stay in control over this stretch.
Expect ATHE to range from $9.00 to $26.48 through 2035. The $14.94 average target implies a +269% move from current prices. That is up +27% on the projected 2034 average. Momentum favours further upside here.
The ATHE price prediction for 2040 points to an average of $22.78 (low $12.29, high $43.61) — a potential gain of +462% on today's $4.05. Buyers look set to stay in control over this stretch.
In 2050, ATHE is projected to trade between $24.14 and $114.79, averaging $53.65 — a potential gain of +12.2x from today's $4.05. That is up +136% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ATHE today (≈ 246.91358 ATHE) could be worth
$13,246.54
+$12,246.54 (+1225%) by 2050 · US Dollar
Based on the average projected ATHE price of $53.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATHEwould be worth at today's price.
$1,000 invested in ATHE on May 27, 2025 (≈ 233.644848 ATHE) would be worth
$946.26
-$53.74 (-5.4%) today · 0.95× · US Dollar
Based on a ATHE entry price of $4.28 vs. today's $4.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.27 | $948.48 | -5.2% |
| 1 month ago | $4.62 | $876.62 | -12.3% |
| 3 months ago | $3.53 | $1,147.31 | +14.7% |
| 6 months ago | $3.6 | $1,125 | +12.5% |
| 1 year ago | $4.28 | $946.26 | -5.4% |
| All time (5.0y) ago | $13.6 | $297.79 | -70.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATHE forecast.
Our base-case forecast reaches $8.10 around 2029.
Implied market cap at $8.10: $146.82M
2026 forecast shows min $3.02, avg $4.14, max $5.52 with ROI 0 and sentiment NEUTRAL. The outlook turns more bullish in subsequent years, with 2027 min $4.01, avg $5.32, max $7.58 and ROI 28.5; sentiment BULLISH.
By 2028 the forecast indicates min $4.61, avg $6.39, max $9.58 and ROI 54.4, with a BULLISH stance. In 2029, the model shows min $6.10, avg $8.77, max $13.66 and ROI 111.8, continuing a BULLISH trajectory. By 2030, the avg price is $10.32 with a min of $6.95 and max of $16.60, and ROI of 149.2, with a BULLISH sentiment.
The path extends to 2031–2035 with continuing gains: 2031 min $6.51, avg $9.96, max $16.50 (ROI 140.6); 2032 min $7.29, avg $11.49, max $19.52 (ROI 177.6); 2033 min $7.50, avg $12.14, max $21.10 (ROI 193.3); 2034 min $7.13, avg $11.86, max $21.04 (ROI 186.4); 2035 min $9.15, avg $15.61, max $28.24 (ROI 277).
The forecast elevates to 2040 with min $12.13, avg $23.33, max $45.73 (ROI 463.5) and remains bullish. In 2050, the model projects min $25.23, avg $56.07, max $123.29 (ROI 1254.4) with a bullish sentiment as the long-term picture.
These numbers imply a sustained upside in the longer horizon, while noting that the estimates are not guarantees and depend on various factors influencing clinical development and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $10.32, with a min of $6.95 and a max of $16.60, and an estimated ROI of 149.2% with a BULLISH sentiment.
The forecast indicates a bullish sentiment from 2027 onward, with rising average prices reaching $10.32 by 2030 and $56.07 by 2050, and a max of $123.29 in 2050. Note that these are estimates and not guaranteed.
Yes. The 2050 forecast lists a max of $123.29, with a bullish outlook and a 1254.4% ROI, suggesting that a price above $100 by 2050 is within the modeled upside.
The current price is $4.14 and the market cap is $78.28M.
For 2040, the forecast shows min $12.13, avg $23.33, max $45.73, with a 463.5% ROI and a BULLISH sentiment.
Alterity Therapeutics Limited Community Discussion
0Share your Alterity Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.